Mapfre (0NQ2)
London Exchange · UK · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 4.335 |
|---|---|
| 52-week range | 3.441 – 4.650 |
| Return, 1 month / 3 months | −1.9% / −3.6% |
| Return, 1 year / 3 years | +12.9% / +156.8% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 51 |
| Volatility (1 year) | 21.6% |
| Worst drawdown (1 year) | -16.1% |
| Average daily value traded | 0.84M EUR |
| Dividend yield | 3.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Mapfre is an insurance group based in Spain. It provides life, general and health insurance to individuals, families and businesses, and it also offers reinsurance and asset management services. Its customers include private policyholders and corporate clients, and it operates across Europe, the Americas and other international markets through its own offices and local subsidiaries. The company's business centres on underwriting insurance policies and managing the related risks.
Mapfre trades under the code 0NQ2 on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Mapfre (0NQ2) trades on the London Exchange in UK. It last closed at EUR 4.335 on 19 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 707 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 12.9% and over the last three months it fell 3.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 71 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 5.2% | ||
| From 52-week high | -5.8% | ||
| Momentum | 54 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -3.6% | ||
| 6-month return | 3.9% | ||
| 12-month return, skipping the last month | 15.0% | ||
| Stability (higher is calmer) | 83 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 21.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.1% | ||
| Liquidity | 51 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.84M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 80 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 3.4% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +2.0% |
|---|---|
| 1 month | −1.9% |
| 3 months | −3.6% |
| 6 months | +3.9% |
| 1 year | +12.9% |
| 3 years | +156.8% |
| 5 years | +212.6% |
Signals
| 50-day / 200-day average | 4.377 / 4.120 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.104 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 26 May 2026 | EUR 0.0894 |
| 26 Nov 2025 | EUR 0.0570 |
| 27 May 2025 | EUR 0.0771 |
| 17 Mar 2025 | EUR 0.0012 |
| 6 Mar 2025 | EUR 0.0012 |
| 27 Nov 2024 | EUR 0.0529 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.